Zydus Lifesciences Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Zydus Lifesciences Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news and updates on Zydus Lifesciences Ltd. from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

14 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus and Beihai Biotech sign an exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market.

pdf

Zydus Lifesciences Ltd.

14 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Stock exchange intimation on closure of USFDA inspection at Zydus'' topical plant.

pdf

Zydus Lifesciences Ltd.

12 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus and Synthon sign an exclusive development, licensing, supply and commercialization agreement for a novel 505(B)(2) oncology product for the US market.

pdf

Zydus Lifesciences Ltd.

12 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

The Company is going to participate in an investor conference 'Kotak: CHASING GROWTH 2025' at Mumbai on Thursday, February 20, 2025

pdf

Zydus Lifesciences Ltd.

11 Feb 2025

981.95

0.74%

Earnings Call

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the post results earnings call held on February 5, 2025

pdf

Zydus Lifesciences Ltd.

10 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Changes in Senior Management

pdf

Zydus Lifesciences Ltd.

07 Feb 2025

981.95

0.74%

New product launches is set to drive growth in US

Buy: Zydus Lifesciences Ltd.

KRChoksey

Zydus Lifesciences’ revenue was largely in-line with our estimates. EBITDA missed our estimates due to lower-than-expected gross profit and higher-than-expected other expenses. However, Adj. PAT was in-line with our estimates as EBITDA miss was offset by lower-than-expected tax expenses.

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

06 Feb 2025

981.95

0.74%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper cutting with regard to publication of unaudited financial results for the quarter / nine months ended December 31, 2024, in Financial Express on February 6, 2025.

pdf